Calviri Scientists Find New Class of Biomarkers for Predicting Treatment Response in Cancer Patients

Calviri Scientists Find New Class of Biomarkers for Predicting Treatment Response in Cancer Patients

header-info

Scientists studying various immune checkpoint inhibitor therapies in patients with advanced lung cancer have found that a new class of blood-based biomarkers— anti-frameshift peptide antibodies, or anti-FSP antibodies— could be developed into improved or orthogonal tests for predicting tumor responses to treatment.

 

Access the full article to read more here.